Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer

被引:19
|
作者
Scheel, Andreas H. [1 ]
Penault-Llorca, Frederique [2 ]
Hanna, Wedad [3 ]
Baretton, Gustavo [4 ]
Middel, Peter [5 ,6 ]
Burchhardt, Judith [5 ]
Hofmann, Manfred [5 ]
Jasani, Bharat [7 ]
Rueschoff, Josef [5 ,7 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Ctr Jean Perrin, Dept Pathol, 58 Rue Montalembert,392, F-63011 Clermont Ferrand 1, France
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Univ Hosp Dresden, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany
[5] Inst Pathol Nordhessen, Germaniastr 7, D-34119 Kassel, Germany
[6] Univ Hosp Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany
[7] Targos Mol Pathol GmbH, Germaniastr 7, D-34119 Kassel, Germany
来源
DIAGNOSTIC PATHOLOGY | 2018年 / 13卷
关键词
HER2/neu; Immunohistochemistry; Breast cancer; Gastric cancer; Magnification rule; Predictive biomarker; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DIGITAL IMAGE-ANALYSIS; AMERICAN-PATHOLOGISTS; PROTEIN EXPRESSION; ADENOCARCINOMAS; REPRODUCIBILITY; RECOMMENDATIONS; PEMBROLIZUMAB; VALIDATION;
D O I
10.1186/s13000-018-0696-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the 'magnification rule': Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods: HER2-IHC was performed on 120 breast cancer biopsy specimens (n = 40 per category). Width and color-intensity of membranous DAB chromogen precipitates were measured by whole-slide scanning and digital morphometry. Image-analysis data were related to semi-quantitative manual scoring according to the magnification rule and to the optical properties of the employed microscope objectives. Results: The semi-quantitative manual HER2-IHC scores are correlated to color-intensity measured by image-analysis and to the width of DAB-precipitates. The mean widths +/- standard deviations of precipitates were: IHC-score 1+, 0.64 +/- 0.1 mu m; score 2+, 1.0 +/- 0.23 mu m; score 3+, 2.14 +/- 0.4 mu m. The width of precipitates per category matched the optical resolution of the employed microscope objective lenses: Approximately 0.4 mu m (40x), 1.0 mu m (10x) and 2.0 mu m (5x). Conclusions: Perceived intensity, width of the DAB chromogen precipitate, and absolute color-intensity determined by image-analysis are linked. These interrelations form the physical basis of the 'magnification rule': 2+ precipitates are too narrow to be observed with 5x microscope objectives, 1+ precipitates are too narrow for 10x objectives. Thus, the rule uses the optical resolution windows of standard diagnostic microscope objectives to derive the width of the DAB-precipitates. The width is in turn correlated with color-intensity. Hereby, the more or less subjective estimation of IHC scores based only on the staining-intensity is replaced by a quasi-morphometric measurement. The principle seems universally applicable to immunohistochemical stainings of membrane-bound biomarkers that require an intensity-dependent scoring.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
    Andreas H. Scheel
    Frédérique Penault-Llorca
    Wedad Hanna
    Gustavo Baretton
    Peter Middel
    Judith Burchhardt
    Manfred Hofmann
    Bharat Jasani
    Josef Rüschoff
    Diagnostic Pathology, 13
  • [2] Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
    Behrens, Hans-Michael
    Warneke, Viktoria S.
    Boeger, Christine
    Garbrecht, Nele
    Juettner, Eva
    Klapper, Wolfram
    Mathiak, Micaela
    Oschlies, Ilske
    Rudolph, Ursula
    Stuhlmann-Laeisz, Christiane
    Trick, David
    Roecken, Christoph
    Hufnagl, Peter
    CANCER MEDICINE, 2015, 4 (02): : 235 - 244
  • [3] Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort
    Karakas, Cansu
    Tyburski, Haley
    Turner, Bradley M.
    Wang, Xi
    Schiffhauer, Linda M.
    Katerji, Hani
    Hicks, David G.
    Zhang, Huina
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 159 (05) : 484 - 491
  • [4] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [5] Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?
    Pirrelli, M.
    Caruso, M. L.
    Di Maggio, M.
    Armentano, R.
    Valentini, A. M.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (02) : 397 - 404
  • [6] Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer
    Liu, Yan-Hui
    Xu, Fang-Ping
    Rao, Jian-Yu
    Zhuang, Heng-Guo
    Luo, Xin-Lan
    Li, Li
    Luo, Dong-Lan
    Zhang, Fen
    Xu, Jie
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (01) : 74 - 79
  • [7] Immunohistochemical antibodies in breast cancer HER2 diagnostics
    Egervari, Kristof
    Szollosi, Zoltan
    Nemes, Zoltan
    TUMOR BIOLOGY, 2008, 29 (01) : 18 - 27
  • [8] HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    CANCERS, 2023, 15 (10)
  • [9] Machine scoring of her2/neu immunohistochemical stains
    Bishop, JW
    Marcelpoil, R
    Schmid, J
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 2002, 24 (05): : 257 - 262
  • [10] A Deep Learning Quantification Algorithm for HER2 Scoring of Gastric Cancer
    Han, Zixin
    Lan, Junlin
    Wang, Tao
    Hu, Ziwei
    Huang, Yuxiu
    Deng, Yanglin
    Zhang, Hejun
    Wang, Jianchao
    Chen, Musheng
    Jiang, Haiyan
    Lee, Ren-Guey
    Gao, Qinquan
    Du, Ming
    Tong, Tong
    Chen, Gang
    FRONTIERS IN NEUROSCIENCE, 2022, 16